17 results about "Antidote" patented technology

The present application relates to a kind of macromolecular heavy metal complexing agent containing 8-hydroxyquinoline and amido phosphate structure and its preparation method, the present application also relates to a kind of heavy metal antidote, and the use of the macromolecular heavy metal complexing agent of the present application in preparing drug for treating heavy metal poisoning.The macromolecular complexing agent of the present application has excellent binding capacity with cadmium, lead, mercury and other heavy metal ions, and is high in safety, has excellent and long-acting heavy metal protection effect.The preparation method of the present application can mass, simply and efficiently prepare the macromolecular complexing agent of the present application, and preparation process is simple, high in yield, raw material is cheap and easy to obtain, reaction condition is mild.

In alternative embodiments, provided are polyheterocyclic uncharged bisoxime antidotes, including polyheterocyclic uncharged bisoximes, and methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein. In alternative embodiments, provided are methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain; or, treating, ameliorating or protecting (preventing) an organophosphate toxicity or poisoning or toxic exposure, or for treating, ameliorating or protecting (preventing) organophosphate inhibition of an acetylcholinesterase (AChE) comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein.

The invention relates to a nucleic acid aptamer DNA sequence as shown in SEQ ID NO.1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient. The invention also discloses application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of antidote drugs used as ricin and / or abrus precatorius toxin.

This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

The invention discloses preparation and application of a skeleton type vomitoxin antidote, and relates to the technical field of feed processing, and the skeleton type vomitoxin antidote is characterized in that the antidote is prepared from 60-70% of Na2S2O5 and 30-40% of a composite carrier through a hot melt extrusion instrument under the conditions that the sleeve outlet temperature is 60-80 DEG C and the screw rotating speed is 30-50 r / min. When the antidote is used for removing vomitoxin in mildewed corn, and the adding level of the effective component skeleton type SMBS is 0.1%, the using effect of the skeleton type vomitoxin antidote is optimal; when the antidote is used for removing DON (deoxynivalenol) in corn alcohol lees polluted by mycotoxin and the addition level of the effective component skeleton-type SMBS is 0.4%, the use effect of the skeleton-type vomitoxin antidote is optimal. A theoretical basis is provided for further development of the corn and the corn alcohol lees in the field of feed processing.

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic aptamers. In particular, the present disclosure provides nucleic acids molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding nucleic acid antidotes, for the modulation of blood coagulation in the context of disease and surgical intervention.

The invention relates to a DNA (deoxyribonucleic acid) aptamer which is shown as a formula I and can be specifically combined with abrus precatorius toxin and exert inhibitory activity and application of the DNA aptamer in prevention or treatment of abrus precatorius toxin poisoning. The nucleic acid aptamer can be combined with the abrus precatorius toxin in a high-affinity and high-specificity mode, and the toxicity of the abrus precatorius toxin is effectively resisted. The invention also designs a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient, and an application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of an abrus precatorius toxin antidote drug. In addition, the nucleic acid aptamer can also be used for resisting the abrus precatorius toxin in vitro or used as a detection tool for detecting the abrus precatorius toxin in environmental and biological samples. The invention provides a new solution for first aid, treatment and detection of the abrus precatorius toxin.

The present invention relates to a detoxifying peptide, characterized in that its sequence comprises the following general amino acid sequence: N-(Val-Gly-X1-X2-Pro-Gly)n-OH, in which: N and OH correspond respectively to the N-terminal and C-terminal end of the peptide; X1 and X2 are chosen from valine (Val), glycine (Gly), threonine (Thr), asparagine (Asn), glutamine (Gln), alanine (Ala), leucine (Leu) and isoleucine (Ile); n is an integer between 1 and 3; for use in the treatment and / or prevention of a disorder associated with glycation and / or glycoxidation of proteins and / or lipids.

The invention provides application of beta-glucuronidase in preparation of an antidote for preventing or / and treating zearalenone poisoning and the antidote for preventing or / and treating zearalenone poisoning, and belongs to the field of feed additives. The invention provides a method for reducing the overall exposure level of ZEN by inhibiting the activity of intestinal bacteria beta-glucuronidase from the perspective of in-vivo exposure control of animals for the first time, and the method is clear in technical path and high in operability. The reduction of the in-vivo exposure level of the ZEN is objectively reflected through the change of in-vivo toxicokinetic parameters (AUC, Cmax and / or MRT), and the technical effect can be quantified and verified. The beta-glucuronidase inhibitor adopted by the invention is wide in source, is especially suitable for the field of feed additives, and has a good application prospect.

The invention discloses a protection application of nicotinamide mononucleotide in APAP liver injury, and the nicotinamide mononucleotide is applied to preparation of a medicine for protecting or treating acetaminophen-induced acute liver injury. The nicotinamide mononucleotide reduces oxidative stress and liver cell apoptosis caused by acetaminophen by activating a nuclear factor erythrocyte 2 related factor 2 signal channel and inhibiting phosphorylation of c-Jun amino terminal kinase. Through dual mechanisms of activating an Nrf2 antioxidant pathway and inhibiting JNK phosphorylation, oxidative stress and cell apoptosis are relieved from the source, and the defect that an existing antidote NAC is narrow in treatment window is effectively overcome; the NMN is used as a direct precursor of NAD < + >, has good stability and high bioavailability, shows the effects of remarkably increasing the survival rate and improving liver functions and tissue pathological damage in experiments, and provides a brand-new multi-target treatment strategy for APAP poisoning.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when detected. The system employs a progressive challenge-response system to detect unresponsiveness, deliver physical stimuli, administer one or more doses of an antidote, and transmit notifications, thereby improving survival rates in overdose situations. The system and methods include a wearable device that acquires physiological information from an opioid user during an opioid use session, analyzes the information to detect respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present invention relates to supramolecular agents presenting on demand reversibility of activity and related methods. The invention in particular relates to supramolecular agents with anticoagulant activity which can be reversed with the use of an antidote agent.

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic activity. In particular, the present disclosure provides nucleic acid molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding antidote nucleic acid molecules capable of modulating anticoagulant activity.

Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are methods of reversing the anti-coagulation effects of the composition by administering an antidote.

The invention belongs to the technical field of traditional Chinese medicine modern preparations, and particularly discloses a centipede toxin-vanquishing decoction nano-micelle transdermal preparation for treating psoriasis and a preparation method thereof.The preparation is prepared from, by weight, 5-15 parts of centipede toxin-vanquishing decoction effective ingredient extract, 20-40 parts of nano-micelle carrier material, 2-8 parts of transdermal absorption enhancer and 37-73 parts of pharmaceutic adjuvants; the centipede toxin-vanquishing drink comprises 3g of centipede, 30g of lithospermum, 30g of rhizoma smilacis glabrae, 30g of ramulus euonymi, 20g of zaocys dhumnade and 10g of liquorice. According to the nano-micelle transdermal preparation for treating psoriasis by adopting the centipede toxin-vanquishing drink and the preparation method of the nano-micelle transdermal preparation, the preparation is based on a classical centipede toxin-vanquishing drink prescription and is combined with a nano-micelle technology, so that the transdermal permeation efficiency of the medicine and the targeting property of a diseased region are improved, the treatment effect is enhanced, the adverse reaction is reduced, meanwhile, the preparation process is stable and controllable, and the cost is low. The method is suitable for industrial production.